Temps réel estimé Cboe BZX  -  20/05 15:38:52
661.55 USD   +0.67%
05/05REGENERON PHARMACEUTICALS, INC. : RBC Capital Markets maintient son opinion neutre
04/05Le bénéfice trimestriel de Regeneron chute en raison des ventes de l'anticorps COVID
04/05Regeneron Pharmaceuticals affiche des bénéfices et des revenus plus élevés au 1er trimestre
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteurAnalyses Zonebourse
Actualités dans d'autres langues sur REGENERON PHARMACEUTICALS, INC.
17/05Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur
13/05High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at ..
13/05High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at ..
10/05TRANSCRIPT : Regeneron Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare C..
04/05Regeneron's COVID drug sales outside U.S. help revenue beat
04/05GLOBAL MARKETS LIVE : Airbnb, Pandora, Apple, Twitter, Meta...
04/05Finally, it's time for Powell's speech
04/05Wall Street lijkt hoger te openen
04/05TRANSCRIPT : Regeneron Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 04, 2022
04/05US Futures Higher Ahead of Fed Funds Rate Announcement, National Employment Report
04/05Futures Wall Street wijzen omhoog
04/05Regeneron Pharmaceuticals Posts Higher Q1 Earnings, Revenue
04/05REGENERON : Q1 Earnings Snapshot
04/05Regeneron quarterly profit drops as COVID antibody sales hit
04/05Earnings Flash (REGN) REGENERON PHARMACEUTICALS Reports Q1 Revenue $2.97B, vs. Street E..
04/05Earnings Flash (REGN) REGENERON PHARMACEUTICALS Reports Q1 EPS $11.49, vs. Street Est o..
04/05Regeneron Reports First Quarter 2022 Financial and Operating Results
02/05Regeneron Announces Investor Conference Presentations
28/04Sanofi Confident In Full-Year Prospects As Dupixent, Consumer Healthcare Drive Strong F..
28/04Sanofi profit gain beats market view on bestseller drug Dupixent
19/04SHAREHOLDER ALERT : Weiss Law Investigates Checkmate Pharmaceuticals, Inc.
19/04SECTOR UPDATE : Health Care Stocks Carried Higher in Rising Tuesday Markets
19/04SECTOR UPDATE : Health Care Stocks Carried Higher in Rising Tuesday Markets
19/04Top Midday Gainers
19/04SECTOR UPDATE : Health Care
19/04Checkmate Pharmaceuticals Shares Take Flight on Regeneron Deal
19/04SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Tuesday
19/04SECTOR UPDATE : Health Care
19/04Regeneron to Buy Checkmate Pharmaceuticals for About $250 Million
19/04Regeneron Pharmaceuticals Agrees to Buy Checkmate Pharmaceuticals in $250 Million All-C..
19/04SpringWorks Therapeutics, Regeneron Collaborate to Test Multiple Myeloma Combination Th..
19/04SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement wi..
19/04Regeneron Pharmaceuticals, Inc. entered into a definitive agreement to acquire Checkmat..
15/04FDA Accepts Regeneron And Sanofi's DUPIXENT (Dupilumab) SBLA For Priority Review
14/04Regeneron Pharmaceuticals' Biologics License Application Review for COVID-19 Treatment ..
14/04U.S. FDA delays decision on Regeneron/Roche COVID antibody therapy
14/04U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab an..
14/04Regeneron Pharmaceuticals, Inc. Announces U.S. FDA Extends Review of Biologics License ..
14/04FDA Extends Review of Regeneron's REGEN-COV Covid-19 Drug
13/04The confusion over inflation
13/04ANALYST RECOMMENDATIONS : CarMax, Boeing, JetBlue, Medtronic, PepsiCo...
12/04INSIDER SELL : Regeneron Pharmaceuticals
11/04INSIDER SELL : Regeneron Pharmaceuticals
11/04INSIDER SELL : Regeneron Pharmaceuticals
08/04Regeneron - dupixent approved by european commission for children aged 6 to 11 years wi..
07/04INSIDER SELL : Regeneron Pharmaceuticals
07/04GLOBAL MARKETS LIVE : Airbus, Berkshire Hathaway, Meta, Samsung, Tesla...
07/04What's in store for investors in 2022?
07/04Regeneron Pharmaceuticals, Sanofi Say EC Expands Dupixent's Marketing Approval to Treat..
06/04ViGeneron GmbH Signs Gene Therapy Strategic Collaboration and Option Agreement with Reg..
05/04Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Confere..
04/04INSIDER SELL : Regeneron Pharmaceuticals
04/04INSIDER SELL : Regeneron Pharmaceuticals
04/04FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and ol..
04/04Regeneron Pharmaceuticals, Sanofi's Dupixent Gets FDA Priority Review for Treatment of ..
04/04FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Old..
04/04Regeneron Pharmaceuticals, Inc. and Sanofi Announce FDA Accepts Dupixent® for Priority ..
01/04INSIDER SELL : Regeneron Pharmaceuticals
01/04INSIDER SELL : Regeneron Pharmaceuticals
01/04CASE LAW : A Review Of Selected Pharmaceutical Patents In The UK Courts During 2020
01/04Regeneron Disclaims An Aflibercept Formulation Patent In Response To Celltrion PGR
30/03INSIDER SELL : Regeneron Pharmaceuticals
29/03Sanofi Sets Dupixent Sales Target at More Than $14.4 Billion
29/03Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupiluma..
29/03Sanofi targets Dupixent peak sales of over 13 bln euros
28/03Regeneron Pharmaceuticals, Inc. - LATE-BREAKING PHASE 3 DATA AT AAD 2022 SHOW DUPIXENT ..
28/03Sanofi-Regeneron's Dupixent Improves Symptoms of Chronic Skin Disease in Late-Stage Stu..
24/03EU medicines regulator recommends AstraZeneca's drug for COVID prevention
23/03INSIDER SELL : Regeneron Pharmaceuticals
23/03INSIDER SELL : Regeneron Pharmaceuticals
22/03Compañías que se deben tener muy en cuenta por técnico este martes en Wall Street
17/03Reino Unido aprueba una terapia preventiva de AstraZeneca contra el COVID-19
17/03Britain approves AstraZeneca's preventative COVID therapy
1  2  3  4  5  6  7  8  9  10Suiv.